Aeolus Pharmaceuticals announced the presentation of new data on AEOL 10150 for the treatment of the pulmonary effects of acute radiation syndrome.
Aeolus Pharmaceuticals (OTCQB:AOLS) announced the presentation of new data on AEOL 10150 for the treatment of the pulmonary effects of acute radiation syndrome.
As quoted in the press release:
The analysis, performed by Jogarao Gobburu, PhD, Vijay Ivaturi, PhD and Hechuan Wang, MS with the Center for Translational Medicine at the University of Maryland School of Pharmacy and funded by Aeolus’ Lung ARS development contract with the Biomedical Advanced Research and Development Authority (“BARDA”) confirmed the statistical significance of the improvement in survival and underlying pathophysiology seen after treatment with AEOL 10150 in NHP efficacy studies conducted by and previously reported by Thomas MacVittie, PhD at the University of Maryland School of Medicine (“UMSOM”).
Dr. Gobburu’s analysis of data from NHP and mouse efficacy studies, performed under the BARDA contract, concluded that administration of AEOL 10150 for 60 days beginning 24 hours after exposure to lethal radiation provided the best survival benefit and that this level of efficacy demonstrated in an “adequate and well designed” study would likely produce a dose modification factor supporting approval under the Animal Rule.